Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Memorial Sloan Kettering Cancer Center · Humanitas University · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
919
total citations
- FWCI
- 106.64
- Percentile
- 100%
- References
- 24
Citations per year
Authors
21Topics & keywords
Topics
Keywords
- Brentuximab vedotin
- Medicine
- Nivolumab
- Internal medicine
- Oncology
- Autologous stem-cell transplantation
- Clinical endpoint
- Transplantation
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.